Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

S. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...

based on the counterparty’s “strategic judgement” on developing MASH therapeutics. Under the original deal signed in July 2019, Seoul, South Korea-based Yuhan was eligible to receive $40 million in up ...

SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals ... a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications.